Hamburg, Germany | Oxford, UK - Evotec AG (ISIN: DE000 5664809, EVT)
today reported strong growth in revenues and profits for the third
quarter 2006. Group revenues of the Hamburg-based drug discovery and
development company increased by 30% to EUR 24.6 million (Q3 2005:
EUR 19.0 million) with all three divisions (Services,
Pharmaceuticals, Tools & Technologies) contributing. The main revenue
drivers include the above average performances in pilot plant and
formulation services, the successful installation of an
ultra-high-throughput screening system in the US as well as a
milestone payment from the Japanese research partner Takeda. The
gross margin in Q3 was therefore particularly high at 39.9%.
As a consequence, Q3 operating result improved by 46% to EUR (4.2)
million (2005: EUR (7.7) million) despite continued higher R&D
investment. As planned, Evotec has increased its R&D expenses for the
third quarter from EUR 3.9 million to EUR 7.3 million due to a higher
investment in proprietary CNS drug development (Pharmaceuticals
Division). The Q3 operating results for the Services and Tools &
Technologies Divisions were positive. The Q3 operating loss before
amortisation for the Evotec Group improved by 28% to EUR (3.1)
million (2005: EUR (4.3) million).
Q3 Highlights:
* Phase II with insomnia drug candidate EVT 201 started
* Development of Alzheimer compound EVT 301 discontinued
* Phase I with Alzheimer/neuropathic pain candidate EVT 101
successfully completed
* Evotec continues development of EVT 101 into Phase II trials:
Roche did not opt in after Phase I, however, expressed continued
interest in further option rights after proof-of-concept
(after period end)
* Second milestone payment received from Takeda
* Drug discovery collaboration initiated with Daiichi
"Q3 was the strongest quarter of the year. Revenues as well as
profits increased significantly over last year. These quarterly
results, although they can not be extrapolated and need to be
evaluated in the 2006 full-year context, indicate that all our
divisions are performing well and we are on track to achieve our
corporate objectives", said Joern Aldag, President & Chief Executive
Officer of Evotec AG. "Our proprietary drug development is
progressing well. We have two promising CNS candidates in our
portfolio, one in Phase II (EVT 201) and one about to enter Phase II
(EVT 101). The first efficacy data in patients should be reported
next year and we are looking forward to this important milestone."
Evotec on track for full year 2006
Evotec revenues for the first nine months 2006 increased by 15% to
EUR 61.2 million (2005: EUR 53.2 million). All three divisions
contributed to revenue growth: Services Division up 10% to EUR 47.7
million (2005: EUR 43.3 million), Pharmaceuticals Division up 155% to
EUR 2.9 million (2005: EUR 1.1 million) as well as Tools &
Technologies Division (third party revenues) up 21% to EUR 10.7
million (2005: EUR 8.9 million).
Gross profit for the first nine months of 2006 increased by
approximately 30% to EUR 23.2 million (2005: EUR 17.9 million),
translating into an improvement in gross margin to 37.9% (2005:
33.6%). R&D expenses for the first nine months increased
substantially as planned from EUR 8.6 million to EUR 24.1 million,
primarily originating from proprietary drug development. All other
operating expenses including SG&A, amortisation of intangible assets,
impairment of goodwill as well as "other operating expenses" amounted
to EUR 21.4 million (2005: EUR 44.4 million). This reduction mainly
results from the fact that such operating expenses 2005 included
charges from acquisition-related goodwill impairment of Evotec
Neurosciences and regular amortisation charges from Evotec's
acquisition of Oxford Asymmetry International in the year 2000, and
that neither occurred in 2006.
As a consequence, group operating result improved by 36% to EUR
(22.3) million (2005: EUR (35.0) million). The operating result in
the Services Division was positive at EUR 1.4 million in the first
nine months of this year. Group net loss declined to EUR 16.1 million
(2005: EUR 35.6 million).
Solid balance sheet structure
Evotec's cash position at the end of September amounted to EUR 57.3
million (end of December 2005: EUR 53.5 million). The increase is
primarily a result of the capital increase in April 2006, partially
offset by higher R&D spend. The equity ratio as of 30 September 2006
was approximately 80%.
Strong order situation, guidance increased
Evotec is increasing its revenue target for the full year 2006: from
EUR 77 million - EUR 81 million to EUR 82 million - EUR 84 million.
Group R&D spend is anticipated to come in at middle of the Company's
guidance (EUR 30 million to EUR 35 million). Based on this adjusted
guidance, Evotec's targeted liquidity position at the end of 2006
increased to over EUR 50 million.
Conference Call
Evotec will hold a conference call today at 02.00 p.m. CET (01.00
p.m. GMT/08.00 a.m. US time East Coast) to discuss the financial
results as well as Q3 progress. Joern Aldag, President & CEO, Dr Dirk
Ehlers, CFO, and Dr John Kemp, Chief Research & Development Officer,
will lead the call.
Conference call numbers (listen only):
Europe: +49.(0)69.2222 3105 (Germany)
+44.(0)20.7138 0827 (UK)
US: +1.718.354 1358
Webcast: www.evotec.com
A replay of the conference call will be available for 24 hours and
can be accessed in Europe by dialing +49.(0)69.22222 0418 (Germany)
or +44.(0)20.7806 1970 (UK) and in the US by +1.718.354 1112. The
access code is 9473629#. The on-demand version of the webcast will be
available on our website: www.evotec.com - Investors - Financial
Reports.
Third Quarter Report 2006
Key figures of consolidated statements of operations according to
IFRS
- condensed -
Evotec AG and Subsidiaries
Euro in thousands except share data and per share data
+----------------------------------------------------------------------------------------+
| | 01-09/ | 01-09/ |Change in| 07-09/ | 07-09/ |Change |
| | 2006 | 2005 | % | 2006 | 2005 | in % |
|--------------------------+----------+----------+---------+----------+----------+-------|
| | | | | | | |
|--------------------------+----------+----------+---------+----------+----------+-------|
|Total revenue | 61,245| 53,247| 15.0| 24,610| 18,966| 29.7|
|--------------------------+----------+----------+---------+----------+----------+-------|
|Cost of revenue | 38,017| 35,332| 7.6| 14,790| 13,295| 11.3|
|--------------------------+----------+----------+---------+----------+----------+-------|
|Gross profit | 23,228| 17,915| 29.7| 9,820| 5,671| 73.2|
|--------------------------+----------+----------+---------+----------+----------+-------|
|Gross margin | 37.9| 33.6| | 39.9| 29.9| |
|--------------------------+----------+----------+---------+----------+----------+-------|
| | | | | | | |
|--------------------------+----------+----------+---------+----------+----------+-------|
|Research and development | 24,083| 8,554| 181.5| 7,262| 3,899| 86.3|
|expenses | | | | | | |
|--------------------------+----------+----------+---------+----------+----------+-------|
|Selling, general and | 17,056| 14,617| 16.7| 5,274| 4,712| 11.9|
|administrative expenses | | | | | | |
|--------------------------+----------+----------+---------+----------+----------+-------|
|Amortisation of intangible| 3,081| 8,785| (64.9)| 1,075| 3,364| (68.0)|
|assets | | | | | | |
|--------------------------+----------+----------+---------+----------+----------+-------|
|Restructuring expenses | -| 866| (100.0)| -| 866|(100.0)|
|--------------------------+----------+----------+---------+----------+----------+-------|
|Impairment of goodwill | -| 18,478| (100.0)| -| -| -|
|--------------------------+----------+----------+---------+----------+----------+-------|
|Other operating expenses | 1,280| 1,656| (22.7)| 391| 529| (26.1)|
|--------------------------+----------+----------+---------+----------+----------+-------|
|Operating loss | (22,272)| (35,041)| (36.4)| (4,182)| (7,699)| (45.7)|
|--------------------------+----------+----------+---------+----------+----------+-------|
| | | | | | | |
|--------------------------+----------+----------+---------+----------+----------+-------|
|Net loss | (16,132)| (35,625)| (54.7)| (4,804)| (7,262)| (33.9)|
|--------------------------+----------+----------+---------+----------+----------+-------|
| | | | | | | |
|--------------------------+----------+----------+---------+----------+----------+-------|
|Weighted average shares |65,795,671|48,405,696| |68,057,204|62,744,415| |
|outstanding (basic) | | | | | | |
|--------------------------+----------+----------+---------+----------+----------+-------|
|Net loss per share | (0.25)| (0.74)| | (0.07)| (0.12)| |
+----------------------------------------------------------------------------------------+
Key figures of consolidated balance sheets according to IFRS
- condensed -
Evotec AG and Subsidiaries
Euro in thousands
+-------------------------------------------------------------------+
| | 30/09/06 | 31/12/05 | Change in % |
|-------------------------------+----------+----------+-------------|
| | | | |
|-------------------------------+----------+----------+-------------|
| Cash and cash equivalents | 57,347 | 53,520 | 7.2 |
|-------------------------------+----------+----------+-------------|
| Net working capital | 4,699 | -1,219 | - |
|-------------------------------+----------+----------+-------------|
| Current and non-current | | | |
| portion of loans and finance | 12,556 | 13,273 | (5,4) |
| lease obligations | | | |
|-------------------------------+----------+----------+-------------|
| Stockholders' equity | 152,620 | 148,669 | 2.7 |
|-------------------------------+----------+----------+-------------|
| | | | |
|-------------------------------+----------+----------+-------------|
| Total assets | 190,832 | 186,111 | 2.5 |
+-------------------------------------------------------------------+
Contact:
Anne Hennecke, Director, Investor Relations & Corporate
Communications, Evotec AG, Phone: +49-40-56081-286,
anne.hennecke@evotec.com
--- End of Message ---
WKN: 566480; ISIN: DE0005664809 ; Index: TecDAX, Prime All Share,
CDAX, HDAX, MIDCAP, TECH All Share;
Listed: Geregelter Markt in Frankfurter Wertpapierbörse, Prime
Standard in Frankfurter Wertpapierbörse,
Freiverkehr in Börse Berlin Bremen, Freiverkehr in Bayerische Börse
München,
Freiverkehr in Börse Düsseldorf, Freiverkehr in Börse Stuttgart,
Freiverkehr in Hanseatische Wertpapierbörse zu Hamburg, Freiverkehr
in Niedersächsische Börse zu Hannover;